AB&B BIO-TECH-B (02627) achieved year-on-year growth in both revenue and net profit in the third quarter.
AB&B BIO-TECH-B (02627) announced that the Group recorded revenue of approximately RMB322 million for the third quarter of 2026, representing a year-on-year increase of approximately 3.5%; net profit was approximately RMB59 million, representing a year-on-year increase of approximately 15.5%.
AB&B BIO-TECH-B (02627) announced that the Group recorded revenue of approximately RMB322 million for the third quarter of 2026, representing an increase of approximately 3.5% compared with the same period last year; and net profit of approximately RMB59 million, representing an increase of approximately 15.5% compared with the same period last year.
The Board considers that the Group achieved year-on-year growth in both revenue and net profit in the third quarter of 2026, with the increase in net profit being more notable, primarily due to the following factors: in the third quarter of 2026, the Group's production batches and output of the trivalent influenza virus subunit vaccine increased compared with the same period last year, and capacity utilization improved; in the third quarter of 2026, the Group continued to optimize internal management and streamline operational processes, resulting in a decrease in administrative expenses compared with the same period last year; and with the optimized pace of R&D investment, R&D expenses in the third quarter of 2026 decreased accordingly compared with the same period last year. The relatively moderate revenue growth of the Group in the third quarter of 2026 was primarily due to the following factors: since 2026, the VAT levy rate applicable to the Group's products has been raised from 3% to 13%, resulting in slower growth in the unit sales revenue of products in the third quarter of 2026; and the unit selling price of the trivalent influenza virus subunit vaccine is approximately 7% lower than that of the quadrivalent influenza virus subunit vaccine. As the sales proportion of the trivalent influenza virus subunit vaccine increased in the third quarter of 2026, the overall average selling price decreased accordingly, causing revenue growth to be lower than sales volume growth.
In the third quarter of 2026, the Company's production, supply and batch release of the influenza virus subunit vaccine continued to progress in an orderly manner, with stable product supply. In terms of production, after obtaining the commercialization license for the trivalent influenza virus subunit vaccine in early 2026, the Group successively completed the production of finished products of the vaccine, and all batches passed internal quality inspection and submitted applications for biological product batch release. As of September 30, 2026, the Group's influenza bulk liquid workshop and influenza formulation workshop had completed 100% and 93.9% of their annual production tasks, respectively. In terms of batch release, as of the end of the third quarter of 2026, the Group had completed a total of 30 biological product batch release applications, of which 17 batches had obtained biological product batch release certificates before September 30, 2026. As of the date of this announcement, the remaining 13 batches have also obtained the relevant certificates. In terms of quality management, the Group passed the Jiangsu Provincial Good Manufacturing Practice (GMP) compliance inspection in the third quarter of 2026. As of the date of this announcement, the Group had passed one national vaccine inspection and two Jiangsu Provincial GMP compliance inspections in 2026. In the fourth quarter of 2026, the Group will continue to respond to market demand during the domestic influenza vaccination season, and continue to advance the production, batch release and market distribution of the trivalent influenza virus subunit vaccine. The Group's sufficient inventory and supply chain reserves will also ensure continued sales growth.
The Board is also pleased to announce that the Company's project "Commercialization of the Class 1 New Drug Quadrivalent Influenza Virus Subunit Vaccine and Promotion of Its Application in Special Populations" recently won the Third Prize of the Jiangsu Provincial Science and Technology Progress Award issued by the Jiangsu Provincial People's Government. This award is official recognition of the technical maturity of the Company's core product, its industrialization capability and its application value for special populations, and also provides strong support for the Company's subsequent efforts to further expand product market coverage and ensure supply quality.
Related Articles

YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.
YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.






